NCT05256862 is a clinical trial of Data collection in Cervical Cancer Screening, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT05256862?

NCT05256862 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT05256862?

Interventions in NCT05256862: Data collection.

What condition does NCT05256862 study?

NCT05256862 studies Cervical Cancer Screening.

Is NCT05256862 still recruiting?

NCT05256862 is currently completed. Last updated 20 March 2025.

Last reviewed 2025-03-20 · How we verify

NCT05256862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania

Completed Last updated 20 March 2025

What this trial tests

trial testing Data collection in Cervical Cancer Screening in 2,974 participants. Completed in 18 October 2024.

Timeline

27 July 2021

Primary endpoint
18 October 2024

18 October 2024

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,974
Start date	27 July 2021
Primary completion	18 October 2024
Estimated completion	18 October 2024
Sites	1 location across Tanzania

Drugs / interventions tested

Data collection — full drug profile →

Conditions studied

Cervical Cancer Screening — all drugs for Cervical Cancer Screening →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 65, female only, with Cervical Cancer Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to analyse the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022). It is to assess the performance of two novel diagnostic tests (QuantiGene-molecular profiling histology (QG-MPH) and PT Monitor® immunoassay) and established tests (Seegene Anyplex™ II 28 HPV Test and Prevo-check®) as potential triage tests for the development of future clinical decision algorithms for CC screening.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Upscaling cervical cancer screening and treatment for women living with HIV at a rural referral hospital in Tanzania: protocol of a before-and-after study exploring HPV testing and novel diagnostics.
Di Salvo I, Mnzava D, Nicoletti GJ, Senkoro E, et al · · 2023 · cited 3× · PMID 36894985 · DOI 10.1186/s12913-023-09113-3

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

NCT07010562 — A Multi-site, Pre-clinical, Prospective Data Collection Study in Patients Undergoing a Right Heart Catheterization · not yet recruiting
NCT07418359 — Comparison of Patient's Physical Activity Levels According to the Physical Activity Level of Their General Practitioner · recruiting
NCT07197398 — Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section · recruiting
NCT06998797 — Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study · not yet recruiting
NCT07529730 — Outcomes of Surgical Treatment in Patients With Infective Endocarditis · completed

Other recruiting trials for Cervical Cancer Screening

Currently open trials in the same condition.

NCT06968871 — Ameliorated Pap Tests and Cervical Cancer Screening Participation · NA · recruiting
NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
NCT07171658 — Breast Cancer-Related Approach for Increasing Cervical Cancer Screening · NA · recruiting
NCT07581873 — Education and Health in Women With Cervical Cancer · NA · active not recruiting
NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05256862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 20 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05256862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing